Trioxsalen
Identification
- Summary
Trioxsalen is a psoralen derivative that has been used in combination with UV light to treat vitiligo, but has been discontinued by its manufacturer.
- Generic Name
- Trioxsalen
- DrugBank Accession Number
- DB04571
- Background
Trioxsalen (trimethylpsoralen, trioxysalen or trisoralen) is a furanocoumarin and a psoralen derivative obtained from several plants, mainly Psoralea corylifolia. Like other psoralens it causes photosensitization of the skin. It is administered either topically or orally in conjunction with UV-A (the least damaging form of ultraviolet light) for phototherapy treatment of vitiligo and hand eczema. The photoactivated form produces interstrand linkages in DNA resulting in cell apoptosis. In research it can be conjugated to dyes for confocal microscopy and used to visualize sites of DNA damage.[3] The compound is has been explored for development of antisense oligonucleotides that can be cross-linked specifically to a mutant mRNA sequence without affecting normal transcripts differing at even a single base pair.
- Type
- Small Molecule
- Groups
- Approved
- Structure
- Weight
- Average: 228.2433
Monoisotopic: 228.07864425 - Chemical Formula
- C14H12O3
- Synonyms
- 2',4,8-Trimethylpsoralen
- 4,5',8-Trimethylpsoralen
- 4,8,5'-Trimethylpsoralen
- 6-hydroxy-β,2,7-trimethyl-5-benzofuranacrylic acid, δ-lactone
- Trimethylpsoralen
- Trioxisaleno
- Trioxsalen
- Trioxysalen
- Trioxysalene
- Trioxysalenum
- Trisoralen
- External IDs
- NSC-71047
Pharmacology
- Indication
Trioxsalen is a pigmenting photosensitizing agent used in conjunction with ultraviolet light in the treatment of vitiligo.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Trioxsalen ispharmacologically inactive but when exposed to ultraviolet radiation or sunlight it is converted to its active metabolite to produce a beneficial reaction affecting the diseased tissue.
- Mechanism of action
After photoactivation it creates interstrand cross-links in DNA, which can cause programmed cell death.
Target Actions Organism ADNA cross-linking/alkylationHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcetohexamide The therapeutic efficacy of Acetohexamide can be increased when used in combination with Trioxsalen. Chlorpropamide The therapeutic efficacy of Chlorpropamide can be increased when used in combination with Trioxsalen. Dexmethylphenidate The serum concentration of the active metabolites of Trioxsalen can be increased when Trioxsalen is used in combination with Dexmethylphenidate. Diazoxide The serum concentration of Trioxsalen can be increased when it is combined with Diazoxide. Doxycycline The therapeutic efficacy of Trioxsalen can be increased when used in combination with Doxycycline. - Food Interactions
- Avoid foods high in furanocoumarins. Eating these foods while you are taking trioxsalen may increase your skin's sensitivity to sunlight. Examples include limes, figs, parsley, parsnips, mustard, carrots, and celery.
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Trisoralen Tab 5mg Tablet 5 mg Oral Icn Pharmaceuticals 1993-12-31 2005-04-26 Canada
Categories
- ATC Codes
- D05BA01 — Trioxysalen
- D05BA — Psoralens for systemic use
- D05B — ANTIPSORIATICS FOR SYSTEMIC USE
- D05 — ANTIPSORIATICS
- D — DERMATOLOGICALS
- Drug Categories
- Antipsoriatics
- Antipsoriatics for Systemic Use
- Antipsoriatics for Topical Use
- Benzopyrans
- Coumarins
- Dermatologicals
- Furocoumarins
- Heterocyclic Compounds, Fused-Ring
- Photosensitizing Agents
- Photosensitizing Agents for Phototherapy
- Psoralens for Systemic Use
- Psoralens for Topical Use
- Pyrans
- Radiation-Sensitizing Agents
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as psoralens. These are organic compounds containing a psoralen moiety, which consists of a furan fused to a chromenone to for 7H-furo[3,2-g]chromen-7-one.
- Kingdom
- Organic compounds
- Super Class
- Phenylpropanoids and polyketides
- Class
- Coumarins and derivatives
- Sub Class
- Furanocoumarins
- Direct Parent
- Psoralens
- Alternative Parents
- 1-benzopyrans / Benzofurans / Pyranones and derivatives / Benzenoids / Heteroaromatic compounds / Furans / Lactones / Oxacyclic compounds / Organooxygen compounds / Organic oxides show 1 more
- Substituents
- 1-benzopyran / Aromatic heteropolycyclic compound / Benzenoid / Benzofuran / Benzopyran / Furan / Heteroaromatic compound / Hydrocarbon derivative / Lactone / Organic oxide show 7 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- psoralens (CHEBI:28329) / Furanocoumarins (C09314)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Y6UY8OV51T
- CAS number
- 3902-71-4
- InChI Key
- FMHHVULEAZTJMA-UHFFFAOYSA-N
- InChI
- InChI=1S/C14H12O3/c1-7-4-12(15)17-14-9(3)13-10(6-11(7)14)5-8(2)16-13/h4-6H,1-3H3
- IUPAC Name
- 2,5,9-trimethyl-7H-furo[3,2-g]chromen-7-one
- SMILES
- CC1=CC2=CC3=C(OC(=O)C=C3C)C(C)=C2O1
References
- General References
- van Coevorden AM, Kamphof WG, van Sonderen E, Bruynzeel DP, Coenraads PJ: Comparison of oral psoralen-UV-A with a portable tanning unit at home vs hospital-administered bath psoralen-UV-A in patients with chronic hand eczema: an open-label randomized controlled trial of efficacy. Arch Dermatol. 2004 Dec;140(12):1463-6. [Article]
- Thazhathveetil AK, Liu ST, Indig FE, Seidman MM: Psoralen conjugates for visualization of genomic interstrand cross-links localized by laser photoactivation. Bioconjug Chem. 2007 Mar-Apr;18(2):431-7. [Article]
- Higuchi M, Yamayoshi A, Kobori A, Yamaoka T, Murakami A: Synthesis and properties of photo-reactive antisense oligonucleotides containing 2'-O-psoralen-conjugated adenosine. Nucleic Acids Symp Ser (Oxf). 2005;(49):331-2. [Article]
- External Links
- Human Metabolome Database
- HMDB0015575
- KEGG Drug
- D01034
- KEGG Compound
- C09314
- PubChem Compound
- 5585
- PubChem Substance
- 46508755
- ChemSpider
- 5383
- BindingDB
- 50240033
- 10844
- ChEBI
- 28329
- ChEMBL
- CHEMBL1475
- ZINC
- ZINC000000002226
- PharmGKB
- PA164747186
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Trioxsalen
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Pill Tablet Oral 5 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 234.5 °C PhysProp - Predicted Properties
Property Value Source Water Solubility 0.0627 mg/mL ALOGPS logP 3.26 ALOGPS logP 2.95 Chemaxon logS -3.6 ALOGPS pKa (Strongest Basic) -2.8 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 1 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 39.44 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 64.86 m3·mol-1 Chemaxon Polarizability 24.77 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9972 Blood Brain Barrier + 0.948 Caco-2 permeable + 0.6552 P-glycoprotein substrate Non-substrate 0.6143 P-glycoprotein inhibitor I Non-inhibitor 0.5919 P-glycoprotein inhibitor II Non-inhibitor 0.8382 Renal organic cation transporter Non-inhibitor 0.8471 CYP450 2C9 substrate Non-substrate 0.7878 CYP450 2D6 substrate Non-substrate 0.8831 CYP450 3A4 substrate Non-substrate 0.6234 CYP450 1A2 substrate Inhibitor 0.9217 CYP450 2C9 inhibitor Non-inhibitor 0.9071 CYP450 2D6 inhibitor Non-inhibitor 0.8415 CYP450 2C19 inhibitor Non-inhibitor 0.7328 CYP450 3A4 inhibitor Inhibitor 0.6141 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.6083 Ames test Non AMES toxic 0.8038 Carcinogenicity Non-carcinogens 0.9169 Biodegradation Not ready biodegradable 0.8998 Rat acute toxicity 1.6608 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9098 hERG inhibition (predictor II) Non-inhibitor 0.9549
Spectra
- Mass Spec (NIST)
- Download (8.79 KB)
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-0h10-0960000000-966d52d94de4b47d3acd Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-004i-0090000000-4c12b8ca5235a37e20b6 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-004i-0190000000-c59336bc58b29152e955 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-004i-0090000000-cdc2f86517847c70c7a6 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-004i-0190000000-b5b18981adcd5409922e Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-01pa-0910000000-5d564225760be9914f3f Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-057i-1950000000-df526964e38f4d627aed Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 159.7991539 predictedDarkChem Lite v0.1.0 [M-H]- 159.9132539 predictedDarkChem Lite v0.1.0 [M-H]- 159.4166539 predictedDarkChem Lite v0.1.0 [M-H]- 153.46445 predictedDeepCCS 1.0 (2019) [M+H]+ 159.9808539 predictedDarkChem Lite v0.1.0 [M+H]+ 160.5062539 predictedDarkChem Lite v0.1.0 [M+H]+ 160.5301539 predictedDarkChem Lite v0.1.0 [M+H]+ 155.82245 predictedDeepCCS 1.0 (2019) [M+Na]+ 160.2402539 predictedDarkChem Lite v0.1.0 [M+Na]+ 160.2212539 predictedDarkChem Lite v0.1.0 [M+Na]+ 160.4012539 predictedDarkChem Lite v0.1.0 [M+Na]+ 161.91557 predictedDeepCCS 1.0 (2019)
Targets
References
- Thazhathveetil AK, Liu ST, Indig FE, Seidman MM: Psoralen conjugates for visualization of genomic interstrand cross-links localized by laser photoactivation. Bioconjug Chem. 2007 Mar-Apr;18(2):431-7. [Article]
- Vasquez KM, Wensel TG, Hogan ME, Wilson JH: High-efficiency triple-helix-mediated photo-cross-linking at a targeted site within a selectable mammalian gene. Biochemistry. 1996 Aug 20;35(33):10712-9. [Article]
- Dardare N, Platz MS: Binding affinities of commonly employed sensitizers of viral inactivation. Photochem Photobiol. 2002 Jun;75(6):561-4. [Article]
- Jimenez-Ruiz A, Zhang Q, Shen CK: In vivo binding of trimethylpsoralen detects DNA structural alterations associated with transcribing regions in the human beta-globin cluster. J Biol Chem. 1995 Dec 1;270(48):28978-81. [Article]
Drug created at September 07, 2007 20:54 / Updated at February 21, 2021 18:51